Prostate cancer, the second most frequent malignancy among men worldwide, can be treated using various antagonists of the androgen receptor, but many patients develop resistance within 18-24 months, and the resistance can block efficacy of not only the first-line antagonist but later-line antagonists as well. Therefore next-generation antagonists based on novel scaffolds are urgently needed.